Amyris, Inc.

171 articles with Amyris, Inc.

• Amyris, Inc. Reports First Quarter 2022 Financial Results

  5/10/2022

  Amyris, Inc., a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform, announced financial results for the first quarter ended March 31, 2022.

• AMYRIS TO HOST FIRST QUARTER 2022 FINANCIAL RESULTS CONFERENCE CALL ON MAY 10

  5/3/2022

  Amyris, Inc. today announced that it will issue its financial results for the first quarter ended March 31, 2022, on the morning of Tuesday, May 10, 2022.

• AMYRIS HOSTS SUCCESSFUL INVESTOR EVENT

  4/14/2022

  Amyris, Inc. successfully hosted an in-person investor event following the Company's Nasdaq Opening Bell Ringing Ceremony.

• Amyris To Participate In The Jefferies Virtual Synthetic Biology Week

  3/17/2022

  Amyris, Inc., a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform announced that management will participate in a fireside chat at the Jefferies Virtual Synthetic Biology Week on Wednesday, March 23, 2022, at 2:00 pm ET.

• AMYRIS CLOSES ACQUISITION OF MENOLABS

  3/11/2022

   Amyris, Inc. today announced that it has closed the acquisition of the assets of MenoLabs, LLC.

• AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS

  3/1/2022

  Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform, today announced financial results for its fourth quarter and full year ended December 31, 2021.

• AMYRIS TO PRESENT AT THE 42nd ANNUAL COWEN HEALTH CARE CONFERENCE

  2/28/2022

  Amyris, Inc. today announced that management will participate in a fireside chat at the 42 nd Annual Cowen Health Care Conference on Monday, March 7, 2022.

• Amyris To Host Fourth Quarter And Full Year 2021 Financial Results Conference Call On March 1

  2/22/2022

  Amyris, Inc. announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2021, on the morning of Tuesday, March 1, 2022, prior to the opening of the financial markets.

• AMYRIS ANNOUNCES APPOINTMENT OF ANA DUTRA TO BOARD OF DIRECTORS

  1/27/2022

  Amyris, Inc. today announced the appointment of Ms. Ana Dutra as its newest independent member of the Amyris Board of Directors, effective January 21, 2022.

• AMYRIS TO ACQUIRE MENOLABS FOR MENOPAUSE WELLNESS ACCELERATING GROWTH OF CONSUMER BUSINESS

  1/24/2022

  Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ operating platform announces that it has agreed to exclusive terms to acquire the assets of MenoLabs, LLC, a women-founded company to treat menopause symptoms, drive research for women's health and improve society's understanding of menopause.

• AMYRIS TO PRESENT AT THE 40th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

  1/5/2022

  Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ operating platform, today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 11:15 am ET.

• AMYRIS AND IMMUNITYBIO COMPLETE JOINT VENTURE FOR NEXT GENERATION COVID-19 RNA VACCINE

  1/3/2022

  Amyris, Inc. (Nasdaq: AMRS), and ImmunityBio (Nasdaq: IBRX), today announced the completion of a previously announced joint venture agreement to accelerate the commercialization of a leading next-generation COVID-19 vaccine.

• 

  Mix-and-Match Vaccine Platform May Boost Immune Response & Duration

  12/3/2021

  IDRI is working with a newly-formed consortium to develop a next-gen COVID-19 vaccine that will be stable at routine temperatures and that may be able to confer immunity for a longer duration.

• Amyris To Present At The Evercore ISI 4th Annual HealthCONx Conference On December 1, 2021

  11/23/2021

  Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market™ operating platform, today announced that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference.

• Amyris To Host Call Regarding Recent Financing Activity

  11/18/2021

  Amyris, Inc. announced that it will host a conference call and live webcast to discuss its recent financing activity on Monday, November 22, 2021 beginning at 6:00 a.m. Pacific Time, John Melo, President and Chief Executive Officer, and Han Kieftenbeld, Chief Financial Officer, will discuss the Company's recent strategic financing.

• Amyris Closes Upsized Offering Of $690.0 Million Of 1.50% Convertible Senior Notes Due 2026

  11/15/2021

  Amyris, Inc., a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, announced that it has closed its offering of 1.50% convertible senior notes due 2026, for gross proceeds of $690.0 million.

• Amyris Prices $600.0 Million Of 1.50% Convertible Senior Notes Due 2026

  11/10/2021

  Amyris, Inc., a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, announced that it has priced $600.0 million aggregate principal amount of 1.50% convertible senior notes due 2026.

• Amyris To Offer $400.0 Million Of Convertible Senior Notes Due 2026

  11/8/2021

  Amyris, Inc., a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market™ operating platform, announced that it proposes to offer $400.0 million aggregate principal amount of convertible senior notes due 2026, subject to market conditions and other factors.

• Amyris, Inc. Reports Third Quarter 2021 Financial Results

  11/8/2021

  Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced financial results for its third quarter ended September 30, 2021.

• Amyris Announces JV Partnership With ImmunityBio For Next Generation COVID-19 RNA Vaccine

  11/8/2021

  Amyris, Inc. (Nasdaq: AMRS), today announced it has entered into a 50:50 joint venture arrangement with ImmunityBio, Inc. (Nasdaq: IBRX), a clinical-stage immunotherapy company, to accelerate the commercialization of a leading next-generation COVID-19 vaccine.